European Society of Cardiology--XXIII congress. New and established therapies.
The annual European Society of Cardiology XXIII Congress was an internationally represented meeting, focusing on the latest developments in cardiac pharmaceutical research and clinical applications. Poster and oral presentations displayed the importance of clinical trials for safety and efficacy of current drugs mainly acting on blocking of signaling pathways in the hyperactivated failing heart or prevention and reversion of vessel occlusions. Additionally, several new drug classes were introduced and tested in small-scale studies. In addition to improved surgical methods discussed at the congress, new classes of minimally invasive treatments were reported, including gene therapy and cell transplantation techniques which could provide additional future cure for cardiac patients.
Brinkmann
K
K
MediGene AG, Lochhamerstrasse 11, D-82152 Martinsried, München, Germany. k.brinkmann@medigene.de